9 of 10 NurOwn-treated ALS patients surpass five-year survival
Nine out of 10 people with amyotrophic lateral sclerosis (ALS) who received the experimental cell therapy NurOwn (debamestrocel)…
Articles by Marisa Wexler, MS
Dazucorilant significantly extends survival in Phase 2 ALS trial
Dazucorilant, an oral cortisol modulator being developed by Corcept Therapeutics, significantly improved survival among people with amyotrophic lateral sclerosis (ALS)…
Brain-computer interface allows man with ALS to talk in real time
An investigational brain-computer interface has allowed a man diagnosed with amyotrophic lateral sclerosis (ALS) to speak in real…
Bipartisan congressional effort calls for increased ALS research funding
A bipartisan team of U.S. congressional legislators is calling for increased funding to support research seeking to better understand and…
Treatment with jacifusen shows benefits for some FUS-ALS patients
Treatment with the experimental therapy jacifusen was generally well tolerated and appeared to slow or even reverse disease progression in…
Mitochondrial abnormalities seen early in many forms of ALS: Study
A study found that genetic mutations associated with amyotrophic lateral sclerosis (ALS) lead to problems with the function and…
Adding low-dose IL-2 to riluzole may improve survival in ALS
Adding a low dose of the anti-inflammatory molecule interleukin-2 (IL-2) to treatment with riluzole is safe and may help extend…
Brain sensor helps decode speech, movement in ALS patient: Study
Implanting a sensor in a region of the brain that helps to control speech was shown in a U.S. study…
1st ALS patient to get Neuralink brain implant finds new voice
Arizona-based Brad Smith has become the first person with amyotrophic lateral sclerosis (ALS) to receive a brain implant from…
Treatment with Tregs safe, may slow ALS progression: Trial
Treatment with regulatory T-cells, or Tregs — a type of anti-inflammatory immune cell — was well tolerated and seemed…